Drugs for 49, Xxxxy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 62)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Heptavalent Pneumococcal Conjugate Vaccine |
|
Phase 4 |
|
|
|
2 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
3 |
|
Cocaine |
Approved, Illicit |
Phase 3 |
|
50-36-2 |
446220 5760 |
Synonyms:
(−)-cocaine
(-)-Cocaine
[1R-(exo,exo)]-3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate, methyl ester
[1R-(exo,exo)]-3-(Benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid, methyl ester
2-Methyl-3beta-hydroxy-1alphah,5alphah-tropane-2beta-carboxylate benzoate (ester)
2-Methyl-3beta-hydroxy-1alphah,5alphah-tropane-2beta-carboxylic acid benzoic acid (ester)
2-Methyl-3b-hydroxy-1alphah,5alphah-tropane-2b-carboxylate benzoate (ester)
2-Methyl-3b-hydroxy-1alphah,5alphah-tropane-2b-carboxylic acid benzoic acid (ester)
2-Methyl-3β-hydroxy-1alphah,5alphah-tropane-2β-carboxylate benzoate (ester)
2-Methyl-3β-hydroxy-1alphah,5alphah-tropane-2β-carboxylic acid benzoic acid (ester)
2-methyl-3β-hydroxy-1αH,5αH-tropane-2β-carboxylate benzoate (ester)
Badrock
Bazooka
b-Cocain
Benzoylethylecgonine
Benzoylmethylecgonine
Bernice
Bernies
beta-Cocain
Blast
Blizzard
Blow
Bouncing Powder
Bump
Burese
Cabello
Candy
Carrie
Caviar
Cecil
Charlie
Chicken Scratch
Cholly
COC
Coca
Cocain
Cocaina
COCAINE
Cocaine Free Base
Cocaine HCL
Cocaine hydrochloride
Cocaine-M
Cocainum
Cocktail
Coke
Cola
Corine
Dama Blanca
Delcaine
Depsococaine
Dextrocaine
D-pseudococaine
Dust
Eritroxilina
|
Erytroxylin
Flake
Flex
Florida Snow
Foo Foo
Freeze
Girl
Gold Dust
Goofball
Green Gold
G-Rock
Happy Dust
Happy Powder
Happy Trails
HCL, Cocaine
Heaven
Hell
Hydrochloride, cocaine
IDS-NC-004
Isocaine
Isococain
Isococaine
Jam
Kibbles N' Bits
Kokain
Kokan
Kokayeen
Lady
L-Cocain
L-Cocaine
Leaf
Methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
Methyl [1R-(exo,exo)]-3-(benzoyloxy)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid
Methyl benzoylecgonine
Moonrocks
Neurocaine
Pimp's Drug
Prime Time
Rock
RX0041
RX-0041
Sleighride
Snort
Star Dust
Star-Spangled Powder
Sugar
Sweet Stuff
Toke
Toot
Trails
Yeyo
Zip
Β-cocain
|
|
4 |
|
Aluminium phosphate |
Approved, Investigational |
Phase 3 |
|
7784-30-7 |
|
Synonyms:
ALUMINIUM PHOSPHATE
ALUMINIUM PHOSPHATE GEL
|
ALUMINUM PHOSPHATE
PHOSPHALJEL
|
|
5 |
|
Fluticasone |
Approved, Experimental |
Phase 2, Phase 3 |
|
90566-53-3 |
4659387 5311101 |
Synonyms:
ADVAIR
Advair®|Avamys®|Flovent HFA®|Veramyst®
FLOVENT HFA
Fluticason
|
Fluticasona
Fluticasone
Fluticasonum
VERAMYST
|
|
6 |
|
Hemagglutinins |
|
Phase 3 |
|
|
|
7 |
|
Agglutinins |
|
Phase 3 |
|
|
|
8 |
|
Bronchodilator Agents |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Anti-Asthmatic Agents |
|
Phase 2, Phase 3 |
|
|
|
10 |
|
Anti-Allergic Agents |
|
Phase 2, Phase 3 |
|
|
|
11 |
|
Xhance |
|
Phase 2, Phase 3 |
|
|
|
12 |
|
Respiratory System Agents |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
Anti-Inflammatory Agents |
|
Phase 2, Phase 3 |
|
|
|
14 |
|
Dermatologic Agents |
|
Phase 2, Phase 3 |
|
|
|
15 |
|
polysaccharide-K |
|
Phase 3 |
|
|
|
16 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 2 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
17 |
|
Aflibercept |
Approved |
Phase 2 |
|
862111-32-8 |
124490314 |
Synonyms:
AFLIBERCEPT
AFLIBERCEPT (GENETICAL RECOMBINATION)
AVE0005
AVE-0005
BAY86-5321
BAY-865321
|
BAY-86-5321
EYLEA
VEGF TRAP
VEGF TRAP-EYE
ZALTRAP
ZIV-AFLIBERCEPT
|
|
18 |
|
Fluorouracil |
Approved |
Phase 2 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
19 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
20 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
21 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
22 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
23 |
|
Pemetrexed |
Approved, Investigational |
Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
24 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
25 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
26 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
27 |
|
Molgramostim |
Investigational |
Phase 2 |
|
99283-10-0 |
|
Synonyms:
|
MOLGRAMOSTIM (GENETICAL RECOMBINATION)
SCH-39300
|
|
28 |
|
N-(2-aminoethyl)-5-isoquinolinesulfonamide |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
30 |
|
Folate |
|
Phase 2 |
|
|
|
31 |
|
Vitamin B9 |
|
Phase 2 |
|
|
|
32 |
|
Vitamin B Complex |
|
Phase 2 |
|
|
|
33 |
|
Folic Acid Antagonists |
|
Phase 2 |
|
|
|
34 |
|
Albumin-Bound Paclitaxel |
|
Phase 2 |
|
|
|
35 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
36 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
37 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
38 |
|
Metformin |
Approved |
Phase 1 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
39 |
|
Aluminum sulfate |
Approved |
Phase 1 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
40 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
41 |
|
Antibodies |
|
Phase 1 |
|
|
|
42 |
|
Ethanol |
Approved |
|
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
43 |
|
Bortezomib |
Approved, Investigational |
|
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
44 |
|
Iron |
Approved |
|
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
45 |
|
Iodine |
Approved, Investigational |
|
|
7553-56-2 |
807 |
Synonyms:
Cadex
Diiodine
I2
Iode
Iodine
Iodine 127
Iodine-127
Iodine-molecule
|
Iodio
iodo
Iodum
Jod
Jood
Molecular iodine
NSC-42355
Tincture iodine
|
|
46 |
|
Mecobalamin |
Approved, Investigational |
|
|
13422-55-4 |
|
Synonyms:
ASIMIL B-12
B-MAX
CO-METHYLCOBALAMIN
MeCbl
Mecobalamin
Mecobalamina
|
Mecobalaminum
Methyl vitamin B12
Methyl(III)cobalamin
Methylcob(III)alamin
Methylcobalamin
|
|
47 |
|
Hydroxocobalamin |
Approved |
|
|
13422-51-0 |
15589840 44475014 |
Synonyms:
a-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
alpha Cobione
alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
ALPHAREDISOL
Axlon
Ciplamin H
Cobalex
Cobalin H
COBALIN-H
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-a-D-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosylbenzimidazole inner salt
Codroxomin
CYANOKIT
Docclan
Docelan
Docevita
Droxomin
Ducobee hy
Duradoce
|
Duralta-12
HEPAVIT
Hydrocobalamin
Hydrogrisevit
Hydrovit
Hydroxocobalamin
Hydroxo-cobalamin
HYDROXOCOBALAMIN ACETATE
HYDROXOCOBALAMIN ANHYDROUS
Hydroxocobalamine
HYDROXOCOBALAMINUM ANHYDROUS
HYDROXOCOBEMINE
Hydroxomin
Hydroxycobalamin
MEGAMILBEDOCE
NEO-CYTAMEN
OH-CBL
Vitamin b-12b
|
|
48 |
|
Testosterone |
Approved, Investigational |
|
|
58-22-0 |
5408 6013 |
Synonyms:
(+-)-8-ISO-TESTOSTERONE
(+-)-RETROTESTOSTERONE
(+)-TESTOSTERONE
(+-)-TESTOSTERONE
(17B)-17-HYDROXY-ANDROST-4-EN-3-ONE
(1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
13-ISO-TESTOSTERONE
17 beta Hydroxy 4 androsten 3 one
17 beta Hydroxy 8 alpha 4 androsten 3 one
17A-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17A-HYDROXY-13A-ANDROST-4-EN-3-ONE
17A-HYDROXY-14B-ANDROST-4-EN-3-ONE
17A-HYDROXY-ANDROST-4-EN-3-ONE
17-beta-Hydroxy-4-androsten-3-one
17BETA-HYDROXY-4-ANDROSTEN-3-ONE
17-beta-Hydroxy-8 alpha-4-androsten-3-one
17B-HYDROXY-(10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-13A-ANDROST-4-EN-3-ONE
17b-Hydroxy-4-androsten-3-one
17B-HYDROXY-8A-ANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ON
17B-HYDROXYANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ONE
17B-HYDROXYANDROST-4-ENE-3-ONE
17B-HYDROXY-D4-ANDROSTEN-3-ONE
17B-TESTOSTERONE
17-HYDROXY-10,13-DIMETHYL-1,2,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
17-HYDROXY-ANDROST-4-EN-3-ONE
17-HYDROXY-D4-ANDROSTEN-3-ONE
17Β-hydroxy-4-androsten-3-one
4-ANDROSTEN-17BETA-OL-3-ONE
4-Androsten-17b-ol-3-one
4-ANDROSTEN-17Β-OL-3-ONE
4-ANDROSTEN-3-ONE-17B-OL
8 Isotestosterone
8-Isotestosterone
8-ISO-TESTOSTERONE
9B,10A-TESTOSTERONE
9B-TESTOSTERONE
Andriol
Andro
Andro 100
Andro L.A. 200
ANDRODERM
Androderm®|Delatestryl®
ANDROGEL
ANDROGEL 1%
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
ANDROPATCH
Andropository 200
Androsorb
ANDROST-4-EN-17B-OL-3-ONE
ANDROST-4-ENE-17B-OL-3-ONE
Androtop
Andrusol
Andryl 200
AstraZeneca brand OF testosterone
Auxilium pharmaceuticals inc. brand OF testosterone
AXIRON
Bartor brand OF testosterone
Beta Testosterone
Bio-T-Gel
CDB 111C
CEPA brand OF testosterone
Cristerona T
Cristerone T
D4-ANDROSTEN-17B-OL-3-ONE
Dea No. 4000
Delatest
DELATESTRYL
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
Dr. kade brand OF testosterone
Epitestosteron
Everone 200
Faulding brand OF testosterone
Ferring brand OF testosterone
FORTESTA
Geno-cristaux gremy
GlaxoSmithKline brand OF testosterone
Hauck brand OF testosterone
Histerone
Homosteron
Homosterone
INTRINSA
Libigel
LUMITESTOSTERON
|
Malerone
Malestrone
Malogen in Oil
Malogen, Aquaspension Injection
MERTESTATE
Metandren
Methyltestosterone
NATESTO
Neo-Hombreol F
Neotestis
Neo-Testis
NSC-9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Ortho brand OF testosterone
Paladin brand OF testosterone
Pasadena brand OF testosterone
Perandren
Percutacrine androgenique
Primotest
Primoteston
RAC-17B-HYDROXY-(13A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(9B,10A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-ANDROST-4-EN-3-ONE
Relibra
RETROTESTOSTERONE
Scheinpharm Testone-Cyp
Schering brand OF testosterone
SmithKline beecham brand OF testosterone
Solvay brand OF testosterone
Sterotate
STRIANT
STRIANT SR
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
TESTIM
TESTIM 1%
Testobase
TESTODERM
TESTODERM TTS
TESTOGEL
Testoject-50
Testolent
Testolin
TESTOPATCH
TESTOPEL
Testopel Pellets
Testopropon
TESTORAL
Testosteroid
TESTOSTERON
TESTOSTERONA
Testosterona [INN-Spanish]
TESTOSTERONE
TESTOSTÉRONE
TESTOSTERONE CIII
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone sulfate
TESTOSTERONUM
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro aq
TESTRONE
Testryl
TOSTRAN
Tostrelle
Tostrex
Trans-Testosterone
Ulmer brand OF testosterone
Unimed brand OF testosterone
Viatrel
Virilon
Virilon IM
Virormone
VIROSTERONE
VOGELXO
Watson brand OF testosterone
|
|
49 |
|
Cyanocobalamin |
Approved, Nutraceutical |
|
|
68-19-9 |
24892734 16212801 44176380 |
Synonyms:
Anacobin
Bedoz
BEHEPAN
Berocca PN
Berubigen
BETALIN 12
Betalin 12 crystalline
Betaline-12
Betolvex
Bevidox
Bevidox concentrate
Biocobalamine
Byladoce
Cabadon m
CALOMIST
Cernevit-12
Cianocobalamina
Cobadoce forte
Cobalin
Cobavite
Cobex
Cobolin-M
Copharvit 5000
Covit
Crystamin
Crystamine
Crysti-12
Crystimin
Crystwel
Cyano-b12
Cyanobalamin concentrate
Cyanocob(III)alamin
CYANOCOBALAMIN
Cyanocobalamin (JP15/usp)
Cyanocobalamin Co 57 Schilling Test Kit
Cyanocobalamine
Cyanocobalaminum
Cyanocobalmin
Cyanoject
CYANOVIT-B12
Cycobemin
Cycolamin
Cykobemin
Cykobeminet
Cyomin
Cyredin
Cytacon
Cytamen
Cytobion
Depinar
Dicopac
Dicopac Kit
Dimethylbenzimidazoylcobamide
Distivit
Docemine
Docibin
Docivit
Dodecabee
Dodecavite
Dodex
Duodecibin
Embiol
Emociclina
Eritrone
|
Erycytol
Erythrotin
Euhaemon
Extrinsic factor
Factor II
Fermin
Fresmin
Hemomin
Hepagon
Hepavis
Hepcovite
Hylugel plus
Infuvite Pediatric
Lactobacillus lactis dorner factor
M.V.I. Pediatric
Macrabin
Megabion
Megalovel
Milbedoce
Millevit
Nagravon
Nascobal
Neuroforte-R
Normocytin
Novidroxin
NSC-80365
Pernaemon
Pernaevit
Pernipuron
Plecyamin
Poyamin
Primabalt
Rebramin
Redamina
Redisol
Rhodacryst
Rubesol
RUBIVITE
Rubramin
RUBRAMIN PC
Rubratope-57 Kit
Rubratope-60 Kit
Rubripca
Rubrocitol
RUVITE
Shovite
Sytobex
Vibal
Vibalt
Vibisone
Virubra
Vitabee 12
VITAMIN B 12
Vitamin b12
Vitamin b12 complex
VITAMIN B12 NOS
Vitamin b12 preparation
vitamine b12
Vitaped
Vitarubin
Vita-rubra
Vitral
VI-TWEL
|
|
50 |
|
Cadexomer iodine |
Experimental |
|
|
94820-09-4 |
|
Synonyms:
|
Interventional clinical trials:
(show top 50)
(show all 88)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (IIV) in Adults 18-49 Years of Age |
Completed |
NCT03101462 |
Phase 4 |
|
2 |
An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age |
Completed |
NCT00192140 |
Phase 4 |
|
3 |
A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 TO 49 YEARS OF AGE IN INDIA |
Active, not recruiting |
NCT05329259 |
Phase 4 |
|
4 |
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age |
Unknown status |
NCT00216242 |
Phase 3 |
|
5 |
Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok® Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age |
Completed |
NCT02290509 |
Phase 3 |
|
6 |
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE |
Completed |
NCT03828617 |
Phase 3 |
|
7 |
A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age. |
Completed |
NCT05045144 |
Phase 3 |
|
8 |
A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age |
Completed |
NCT00860067 |
Phase 2, Phase 3 |
|
9 |
A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent Virus-Like Particle Influenza Vaccine in Healthy Adults 18-49 Years of Age |
Completed |
NCT03321968 |
Phase 3 |
|
10 |
Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 Years |
Completed |
NCT00539981 |
Phase 3 |
|
11 |
A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age |
Completed |
NCT00952705 |
Phase 3 |
|
12 |
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY) |
Completed |
NCT03547167 |
Phase 3 |
|
13 |
A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years |
Completed |
NCT00192335 |
Phase 3 |
|
14 |
A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Consistency of Three Consecutive Lots of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs in Healthy Subjects Aged 18 to 49 Years |
Completed |
NCT00617851 |
Phase 3 |
|
15 |
Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. |
Completed |
NCT00328107 |
Phase 2, Phase 3 |
|
16 |
A Phase II/III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 18-49 Years |
Completed |
NCT03390166 |
Phase 2, Phase 3 |
|
17 |
A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population |
Completed |
NCT01734239 |
Phase 3 |
|
18 |
A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old |
Recruiting |
NCT05054322 |
Phase 2, Phase 3 |
Fluticasone Propionate |
19 |
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. |
Recruiting |
NCT05513053 |
Phase 3 |
|
20 |
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age |
Active, not recruiting |
NCT04605159 |
Phase 3 |
Placebo |
21 |
A Phase III, Randomized, Open-label, Active Vaccine-controlled Crossover Study to Evaluate the Reactogenicity, Safety and Immune Response of Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Girls From 9 to 17 Years of Age, and in Non-pregnant Adult Women From 18 to 49 Years of Age |
Active, not recruiting |
NCT05169905 |
Phase 3 |
|
22 |
A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age |
Active, not recruiting |
NCT05464420 |
Phase 3 |
|
23 |
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers |
Active, not recruiting |
NCT04980391 |
Phase 3 |
Placebo |
24 |
A Randomized, Observer-Blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-49 Years of Age |
Not yet recruiting |
NCT05040789 |
Phase 3 |
|
25 |
A Phase IIIB, Open Label, Non-randomized, Controlled, Multi-country Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Repeat Vaccination With 120 µg Dose of RSV Maternal Vaccine During Subsequent Pregnancy in Healthy Maternal Participants 18-49 Years of Age |
Withdrawn |
NCT05229068 |
Phase 3 |
|
26 |
A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE |
Completed |
NCT04071158 |
Phase 2 |
|
27 |
Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years |
Completed |
NCT02669121 |
Phase 2 |
|
28 |
Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years |
Completed |
NCT00845429 |
Phase 2 |
|
29 |
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults |
Completed |
NCT02307851 |
Phase 2 |
|
30 |
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85 |
Completed |
NCT04473690 |
Phase 1, Phase 2 |
|
31 |
A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS |
Completed |
NCT04032093 |
Phase 2 |
|
32 |
A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49 |
Completed |
NCT01147068 |
Phase 1, Phase 2 |
|
33 |
A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE |
Completed |
NCT03170609 |
Phase 2 |
|
34 |
Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years |
Completed |
NCT01612000 |
Phase 1, Phase 2 |
|
35 |
Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age |
Completed |
NCT00623181 |
Phase 2 |
|
36 |
A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 Years to 49 Years |
Completed |
NCT02894840 |
Phase 1, Phase 2 |
|
37 |
A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older. |
Completed |
NCT01224262 |
Phase 1, Phase 2 |
|
38 |
A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years |
Completed |
NCT01320696 |
Phase 1, Phase 2 |
|
39 |
OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study. |
Completed |
NCT01802684 |
Phase 2 |
|
40 |
A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49% |
Recruiting |
NCT04856176 |
Phase 2 |
Granulocyte-Macrophage Colony-Stimulating Factor;Pembrolizumab;pemetrexed;Paclitaxel;Carboplatin |
41 |
A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE |
Active, not recruiting |
NCT04766086 |
Phase 2 |
|
42 |
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain |
Not yet recruiting |
NCT05560646 |
Phase 2 |
OG-6219;Placebo |
43 |
Phase I Randomized Double Blind Placebo-controlled Study of Universal Influenza Vector Vaccine "UniFluVec" of Two Dose Levels After Two Intranasal Administrations in Healthy Volunteers at the Age From 18 to 49 Years Old |
Completed |
NCT04650971 |
Phase 1 |
|
44 |
A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet β-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin |
Completed |
NCT01933256 |
Phase 1 |
HIP2B;Placebo |
45 |
A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age |
Completed |
NCT00641017 |
Phase 1 |
|
46 |
A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study |
Completed |
NCT00730457 |
Phase 1 |
|
47 |
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years |
Completed |
NCT03343626 |
Phase 1 |
Placebo |
48 |
A Phase 1, Randomized, Controlled, Observer-blinded Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults Aged 18 To 49 Years |
Completed |
NCT02955160 |
Phase 1 |
|
49 |
Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years. |
Completed |
NCT00599443 |
Phase 1 |
|
50 |
A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years. |
Completed |
NCT03594890 |
Phase 1 |
|
|